Total synthesis of remdesivir
- PMID: 34908617
- PMCID: PMC8656175
- DOI: 10.1016/j.tetlet.2021.153590
Total synthesis of remdesivir
Abstract
Remdesivir, the first drug approved by the FDA to treat COVID-19, is in high demand for patients infected with the SARS-CoV-2 virus. Herein, we report a facile approach minimizing the protecting group manipulations to afford remdesivir in good overall yield.
Keywords: COVID-19; Nucleoside; Nucleotide; RdRp; Remdesivir.
© 2021 Elsevier Ltd. All rights reserved.
Conflict of interest statement
The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Srivari Chandrasekhar reports financial support was provided by Science and Engineering Research Board.
Figures
References
-
- Zhou P., Yang X.-L., Wang X.-G., Hu B., Zhang L., Zhang W., Si H.-R., Zhu Y., Li B., Huang C.-L., Chen H.-D., Chen J., Luo Y., Guo H., Jiang R.-D., Liu M.-Q., Chen Y., Shen X.-R., Wang X., Zheng X.-S., Zhao K., Chen Q.-J., de F., Liu L.-L., Yan B., Zhan F.-X., Wang Y.-Y., Xiao G.-F., Shi Z.-L. Nature. 2020;579:270–273. - PMC - PubMed
-
- Kupferschmidt K., Cohen J. Science. 2020;367:610–611. - PubMed
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous
